Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT05410470
Status
Completed

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor currently used in the treatment of Myelofibrosis (MF). Ruxolitinib confirmed improvements in splenomegaly, MF-related symptoms and survival benefit in COMFORT and JUMP studies. At present, the real-world data on the efficacy and safety of ruxolitinib in the treatment of MF in China is still insufficient. The aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with MF and to provide guidance for the usage of ruxolitinib in MF in China.This was a retrospective, multicenter study of MF patients who received ruxolitinib treatment in Shandong province from August 2012 to December 2021. Data were analyzed using SPSS. Overall survival (OS) and Event-free survival (EFS) were estimated using the Kaplan- Meier method.

Key Dates

Start date
Aug 31, 2012
Status verified
May 2022
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
130 participants (actual)

Arms

  • Arm: MF patients who received ruxolitinib treatment

Primary Outcome Measure

The proportion of patients with a ≥35% reduction in palpable spleen volume from baseline. [ Time Frame: From Week 0 through Week 24 ]

Related Studies